PAVM — PAVmed Inc.

Summary of PAVmed Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: PAVmed reported a GAAP net loss of $1.1 million for Q1 2026, a significant decline from a profit of $18.6 million in the prior year, primarily due to changes in the fair value of Lucid shares.
• Cash Position: As of March 31, 2026, cash stood at $6.5 million, not including anticipated proceeds from warrant exercises related to Lucid and Veris.
• Shares Outstanding: Approximately 7.3 million shares outstanding, with a GAAP loss per share of $4.42 after accounting for preferred dividends.
• Operating Expenses: Non-GAAP operating expenses increased to $5.9 million, reflecting higher R&D costs for Veris and general administrative expenses related to recapitalization.

2. Strategic Updates and Business Highlights

• Capital Structure: PAVmed completed a restructuring of its capital structure, eliminating legacy preferred stock and convertible debt, which positions the company for growth.
• Medical Device Portfolio: The company is relaunching its medical device portfolio under new leadership, focusing on products like PortIO and endoscopic imaging technology from Duke.
• Lucid Diagnostics: PAVmed is awaiting Medicare coverage for Lucid, which is expected to be transformative. Lucid has also secured initial orders from the VA and positive coverage from a commercial payer.
• Veris Platform: The commercial rollout with Ohio State University is progressing, with plans to expand to additional departments. The implantable physiologic monitor is on track for submission by year-end.

3. Forward Guidance and Outlook

• PAVmed is optimistic about its position post-restructuring, aiming to explore new opportunities and expand its medical device portfolio.
• The company anticipates that Lucid's upcoming milestones, including Medicare coverage and capital raises, will enhance PAVmed's financial position and operational capabilities.
• Continued focus on R&D for Veris is expected to drive future growth, with a goal of reaching 1,000 patients enrolled in the registry within the first year.

4. Bad News, Challenges, or Points of Concern

• Financial Losses: The significant shift from profit to loss raises concerns about financial stability and operational efficiency.
• Cash Reserves: The current cash position may limit immediate growth opportunities until additional capital is raised.
• Delayed Medicare Coverage: Ongoing delays in Medicare coverage for Lucid Diagnostics have caused frustration and uncertainty regarding revenue generation.
• Operational Challenges: Initial delays in EHR integration and the complexity of managing patient data and alerts at OSU highlight potential operational hurdles.

5. Notable Q&A Insights

• Expansion Opportunities: PAVmed is open to exploring technologies outside North America but primarily sources innovations from U.S. academic medical centers.
• Focus Areas: The company remains flexible in pursuing opportunities across medical devices, diagnostics, and therapeutics, with a particular interest in high-margin, less commoditized products.
• Patient Enrollment: While specific enrollment numbers for Veris were not disclosed, the company confirmed that it is on track to meet its target of 1,000 patients, despite some initial delays.
• Commercialization Timeline: Future commercialization efforts will depend on capital availability, with discussions ongoing with other cancer centers and practice networks.

This summary encapsulates the key points from PAVmed's Q1 2026 earnings call, providing a balanced view of the company's financial health, strategic direction, and operational challenges.